A Feasibility Study of De-escalation of Chemotherapy in Patients with Early-Stage HER2 Positive Breast Cancer
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Carboplatin (Primary) ; Docetaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
Most Recent Events
- 08 Oct 2024 Planned End Date changed from 1 Jun 2026 to 1 Jun 2027.
- 08 Oct 2024 Planned primary completion date changed from 1 Jun 2025 to 1 Jun 2026.
- 08 Oct 2024 Planned initiation date changed from 1 Jun 2023 to 11 Aug 2025.